Oechsner M, Groenke L, Mueller D
Neurologische Klinik, Universitaetskrankenhaus Eppendorf, Hamburg, Germany.
Acta Neurol Scand. 2000 Apr;101(4):283-5. doi: 10.1034/j.1600-0404.2000.101004283.x.
This is the first report of a histologically confirmed pleuropulmonary fibrosis (PPF) associated with the dopamine agonist dihydroergocryptine.
A 67-year-old male patient with Parkinson's disease developed a severe restrictive pulmonary disorder with dyspnea and nonproductive cough after a daily intake of 45 mg dihydroergocryptine for 2 years. After changing the dopamine agonist to the non-ergoline substance pramipexole, marked improvement of the clinical symptoms of PPF occurred, while radiological signs showed only a moderate decrease.
PPF is a possibly fatal complication. Chest X-rays and specific pneumological diagnostics should be done if typical symptoms or nonspecific signs of PPF occur while a patient is on treatment with an ergoline dopamine agonist.
这是首例经组织学证实的与多巴胺激动剂二氢麦角隐亭相关的胸膜肺纤维化（PPF）报告。
一名67岁帕金森病男性患者，在每日服用45毫克二氢麦角隐亭2年后，出现严重的限制性肺部疾病，伴有呼吸困难和干咳。将多巴胺激动剂换为非麦角林类药物普拉克索后，PPF的临床症状明显改善，而放射学征象仅略有减轻。
PPF是一种可能致命的并发症。在患者接受麦角林类多巴胺激动剂治疗期间，如果出现PPF的典型症状或非特异性体征，应进行胸部X线检查和特定的肺部诊断。
